Certara Services Archives

Blog

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…

Jim Gallagher2021 年 12 月 15 日

Case Study

Dose Optimization Using Population PK for an Orphan Drug

RAPALIMUS® Tablets (sirolimus) is Nobelpharma’s orphan drug developed from an oral medication that is sold…

Jim Gallagher2021 年 11 月 17 日

Case Study

通过以数据为导向的科学方法，确定进入市场的路径战略

How Certara supported a gene therapy manufacturer by using a selection of gateway and value…

Jim Gallagher2021 年 10 月 28 日

White Paper

Using Real-world Evidence to Advance Market Access for New Therapeutics

Jim Gallagher2021 年 9 月 29 日

On-Demand Webinar

罕见病管理的“可怕”未来

In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…

Jim Gallagher2021 年 9 月 23 日

Blog

Succeeding in Value Communication: Introduction

Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…

Danny Hudzinski2021 年 8 月 5 日

视频

What is BaseCase?

Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…

Jim Gallagher2021 年 7 月 20 日

Blog

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…

Danny Hudzinski2021 年 6 月 18 日

On-Demand Webinar

Three Pathways have emerged in Innovative Access Agreements

The days of simply determining the market demand for a new drug as a function…

Jim Gallagher2021 年 6 月 11 日

On-Demand Webinar

Outcomes Based Agreements

The days of simply determining the market demand for a new drug as a function…

Jim Gallagher2021 年 6 月 11 日

Certara 服务

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

Dose Optimization Using Population PK for an Orphan Drug

通过以数据为导向的科学方法，确定进入市场的路径战略

Using Real-world Evidence to Advance Market Access for New Therapeutics

罕见病管理的“可怕”未来

Succeeding in Value Communication: Introduction

What is BaseCase?

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

Three Pathways have emerged in Innovative Access Agreements

Outcomes Based Agreements

订阅时事通讯

快捷链接

解决方案

联系我们